Dr. Reddy's plots new assault on U.S. market

Indian drugmaker Dr. Reddy's Laboratories plans to launch about seven new generics in the United States this year and next, including its version of AstraZeneca's reflux drug Prilosec, a company official said in an interview with Reuters. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.